Weekly Summary 

The healthcare sector delivered mixed performance over the past week: strong in the United States, with the S&P 500 Health Care Index rising +2.16%, which was relatively in line with the broader market (+2.51%); while performance in Europe was more moderate, with a gain of +0.94%, underperforming the Stoxx Europe 600 (+2.37%). These results come amid sector rotation, as investors are diversifying their portfolios beyond technology stocks, leading to renewed interest in the healthcare sector for more than three months. Over the week, this trend was driven by large-cap pharmaceutical stocks (+2.37%). The biotech sector, which is more sensitive to high interest rates and financing needs, fell by 0.55%.

The clinical news flow remains quiet this November: Rezolute announces positive results in tumor-induced hyperinsulinism; in immunology, the market is awaiting phase II data on Kymera’s KT-621 by the end of the year, which represents a potential competitor to Dupixent (Sanofi) in atopic dermatitis.

Regulatory news underscores the importance of the level of evidence: the FDA has refused to approve Summit’s ivonescimab as a second-line treatment for EGFR-mutated lung cancer, due to the lack of a statistically significant benefit in overall survival.

M&A activity remains strong: argenx acquires Unnatural Products for up to $1.15bn; Oura plans to acquire Counsel Health to link biometric data with medical consultations.

On the political front, in the wake of the Democrats’ victory in Congress: CMS is granting a six-month grace period for the implementation of the new Medicaid requirements; the Democratic Party is considering a new “Medicare for More” approach rather than the highly controversial “Medicare for All” proposal; and the resurgence of measles in the United States serves as a reminder of the consequences of declining vaccination rates.

PDF Downloader (FR)

Name(Required)